Purpose {#sec1}
=======

Breast cancer is the second most common cancer in the world and, by far, the most frequent cancer among women, with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% of all cancers) \[[@cit0001]\]. Ipsilateral breast tumor recurrence (IBTR) after surgery and adjuvant therapy is recorded in up to 20% of patients within 15 years after initial therapy \[[@cit0002]\]. Several prognostic factors influencing the risk of IBTR have been reported including age, tumor characteristics inherited susceptibility, treatment concepts of the primary tumor, and lifestyle factors like obesity and alcohol consumption \[[@cit0003]\]. However, early-stage low-risk tumors with favorable prognostic characteristics are known to show a significantly smaller risk for local tumor recurrence \[[@cit0004],[@cit0005]\], with 5-year rates of only one to 2% \[[@cit0006]\].

Initially, standard therapy for women with all tumor stages was mastectomy. In the early 1980's, breast conserving therapy (BCT) was established for small, low-risk tumors, combining lumpectomy plus adjuvant radiation therapy \[[@cit0007]\]. Nevertheless, if local breast tumor recurrence is diagnosed after previous whole-breast radiotherapy, mastectomy still remains the gold-standard therapy according to current national and international guidelines. However, several studies reported high levels of psychosocial distress negatively affecting quality of life in some women undergoing mastectomy \[[@cit0008]\]. Hence, some women refuse this form of radical, mutilating surgery and request for alternative treatment options. Some authors therefore considered the possibility of a second BCT with salvage lumpectomy as sole therapy for small local recurrences with favorable tumor characteristics \[[@cit0009]\]. However, significantly increased second IBTR rates of up to 20% after 5 years have been reported for lumpectomy alone \[[@cit0010],[@cit0011],[@cit0012],[@cit0013]\]. Consequently, the addition of post-operative re-irradiation following lumpectomy was proposed to reduce the rates of second IBTR \[[@cit0003],[@cit0014],[@cit0015],[@cit0016],[@cit0017],[@cit0018],[@cit0019],[@cit0020],[@cit0021]\]. As studies reporting outcomes following re-irradiation with local brachytherapy for women with small, low-risk IBTR treated with second lumpectomy are still rare, the efficacy and toxicity of this individual treatment concept were evaluated at the Department of Radiooncology at the Heidelberg University Hospital.

Material and methods {#sec2}
====================

In total, 19 patients with IBTR were re-irradiated using multi-catheter brachytherapy at the Heidelberg University Hospital between January 2008 and September 2018. All patients received a breast-conserving surgery for the primary tumor with sentinel lymph node biopsy (5 patients) or axillary lymph node dissection (12 patients), followed by whole breast external beam radiation therapy (EBRT) with or without regional nodal irradiation, depending on the pathological axillary lymph node status. Whole breast irradiation of the primary tumor was performed with a total dose of 50.4 Gy in fractions of 1.8 Gy and an additional boost irradiation of 8-16 Gy was performed in 16 patients. One patient received additional irradiation of the supraclavicular lymphatic drainage, with the same total dose and number of fractions. Systematic adjuvant treatment was administered according to guidelines. Six patients received adjuvant chemotherapy: one patient was treated with epirubicin and cyclophosphamide, two patients received cyclophosphamide, methotrexate and 5-fluorouracil, while one patient was treated with mitoxantrone. Furthermore, epirubicin, cyclophosphamide, and 5-fluorouracil were administered in two patients. Fourteen patients received endocrine therapies according to their hormone receptor status. Endocrine therapy consisted of tamoxifen in 13 cases, while one patient was treated with an aromatase inhibitor. Patients were followed up according to German and international treatment guidelines.

Ipsilateral breast tumor recurrence was defined as local recurrence within the pre-treated breast. All patients with biopsy-proven IBTR were staged for locoregional and distant metastases according to current guidelines. Mastectomy was offered as standard therapy to all patients. For patients with low-risk IBTR with maximum rpT1 cN0 cM0 tumors and preferably positive hormone receptor status without overexpression of Her2 (human epidermal growth factor receptor 2) who refused modified radical mastectomy, a second BCT was considered. Multifocal tumors were not treated with a second BCT. The decision for a second BCT was further influenced by the initial therapy, the ability to obtain negative resection margins, and the possibility of preserving a reasonable cosmetic result.

Second BCT was performed via re-excision and re-irradiation of the tumor bed, using high-dose-rate (HDR brachytherapy) or pulsed-dose-rate (PDR brachytherapy) multi-catheter interstitial brachytherapy. Post-implant CT-based treatment planning was performed. For appropriate localization of the former tumor bed, preoperative clinical examination, preoperative imaging (mammograms, ultrasound, and MRI if available; *n* = 4 patients), surgical reports, position of the skin scar, and surgical clips (*n* = 4 patients) were taken into consideration. Post-operative ultrasound was additionally applied for identification of the tumor cavity and post-operative tissue changes. Clinical target volume (CTV) was created by delineation of the tumor bed and non-isotropic geometrical expansion. In each direction, the safety margin was calculated by taking into account the size of the free resection margin in the respective direction. CTV contouring was based on the slightly modified recommendations by the GEC-ESTRO Breast Cancer Working Group \[[@cit0022]\]. In detail, the safety margin had to be at least 10 mm (in case of R0 resection), up to a maximum of 20 mm (in case of close margin resection). As treatment was performed with multi-catheter brachytherapy, no additional PTV margin was added. Dose constraints were used in line with the ESTRO-ACROP guideline \[[@cit0023]\]. A typical HDR brachytherapy treatment plan is shown in [Figure 1](#f0001){ref-type="fig"}.

![Treatment plan with dose-volume histogram](JCB-11-37355-g001){#f0001}

Eleven patients received HDR brachytherapy and 8 patients PDR brachytherapy using ^192^Ir afterloading. For HDR brachytherapy, a total dose of 34.2 Gy in fractions of 3.8 Gy (*n* = 9) or 32 Gy in fractions of 4 Gy (*n* = 2) was applied in two fractions per day. PDR brachytherapy was performed one pulse per hour using a total dose of 50 Gy in pulses of 0.5 Gy (*n* = 4), 49.8 Gy in pulses of 0.6 Gy (*n* = 2), 50.4 Gy in pulses of 0.6 Gy (*n* = 1) or 0.7 Gy (*n* = 1). A classical flexible plastic catheter technique was applied. The number of catheters ranged between 7 and 21. Minimal distance between implant and thoracic wall as well as between implant and skin had to be more than 5 mm and at least 1 cm for reducing skin toxicity, respectively. Treatment plans were optimized using treatment planning system PLATO (Nucletron, Veenendaal, The Netherlands) until 2010 and Oncentra Brachy (Nucletron, now Elekta AB, Stockholm, Sweden) afterwards. Treatment delivery was performed with microSelectron PDR or microSelectron HDR units (Nucletron, now Elekta), respectively.

Patient data were retrieved retrospectively from institutional databases in accordance with institutional ethical policies. For patients who received their initial whole breast irradiation outside of the Heidelberg University Hospital, all treatment-related documents were collected. Analyses of surgical and pathological reports as well as reviews of treatment plans were performed. Overall survival (OS) was calculated in months from the start of brachytherapy until the last date of follow-up or death. Disease-free survival (DFS) as well as local control (LC) and locoregional control (LRC) were calculated from the start of brachytherapy until the first diagnosis of recurrent disease. Local recurrence was defined as any relapse within the ipsilateral breast tissue, while regional recurrence was considered as occurrence of regional lymph node metastases (axilla, supraclavicular fossa, internal mammary chain). Recurrences at any other sites were classified as distant metastases. The data analysis was censored as not all patients suffered from an event during follow-up time. Kaplan-Meier method was used to estimate survival rates of OS, DFS, LC, and LRC. Kaplan-Meier plots were generated using a software tool SPSS 24.0. Acute toxicity was defined as occurence of side effects within 3 months following brachytherapy, while later occurence was classified as late toxicity. Toxicity was evaluated according the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The present study was approved by the ethics committee of the Medical Faculty of Heidelberg University (S-047/2016).

Results {#sec3}
=======

Patient characteristics {#sec3.1}
-----------------------

Patient and treatment characteristics are illustrated in [Table 1](#t0001){ref-type="table"}. Patients' median age at the time of initial breast cancer diagnosis and of IBTR was 50.4 years and 63.7 years, respectively. Most IBTRs occurred in or close to the primary tumor site: 79% (*n* = 15) were detected in the same quadrant, 11% (*n* = 2) in the nearby quadrant, and another 11% (*n* = 2) in a different quadrant of the breast. One patient was simultaneously diagnosed with contralateral breast cancer and IBTR. Primary tumors as well as IBTRs were staged pTis to pT1c, with an average tumor size of 11 mm and 12 mm, respectively. For the primary tumors, histological lymph node status was documented in nearly 90% of patients. After diagnosis of the primary tumor, 63% (*n* = 12) of patients received axillary lymph node dissection, while sentinel lymph node biopsy was performed in 26% (*n* = 5) of cases. For 11% of patients (*n* = 2), there was no histological lymph node status documented. At the time point of IBTR, second axillary dissection was not performed in 89% (*n* = 17) of the cases to reduce the risk of lymphedema. In three cases, histology of IBTR differed from histology of the primary tumor: two patients were diagnosed with invasive lobular carcinomas as primary tumors and invasive ductal carcinomas as IBTR, while one patient suffered from an invasive ductal carcinoma as primary tumor and was diagnosed with an invasive mucinous carcinoma as IBTR. Changes in the receptor status were detected in three other women: while the primary tumor of two patients was Her2 positive, local recurrences were Her2 negative. One woman was initially diagnosed with hormone receptor negative breast cancer, while IBTR was an estrogen and progesterone receptor-positive tumor.

###### 

Patients, tumors, and treatments characteristics

  Characteristic              Primary tumor   IBTR                                               
  --------------------------- --------------- ------ ------------- ------------------ ---- ----- ----------------
  Age at diagnosis (years)                                         50.4 (41-71)                  63.7 (55-85)
  Time to IBTR (months)                                                                          159.8 (27-290)
  EBRT                        Dose (Gy)       19                   50.4 (50.4-50.4)              
  Boost (Gy)                  16              84     11.4 (8-16)                                 
  pT size (mm)                                                     11 (5-21)                     12 (5-24)
  Tumor location (quadrant)   Same                   15            78                            
  Nearby                      2               11                                                 
  Other                       2               11                                                 
  Histology                   Lobular         2      11                               1    5     
  Ductal                      4               21                   10                 53         
  Mucinous                    0               0                    1                  5          
  DCIS                        3               16                   1                  5          
  Unknown                     10              52                   6                  32         
  pN status                   pN0             15     78                               5    26    
  pN1a                        2               11     0             0                             
  \> pN1a                     0               0      0             0                             
  Unknown                     2               11     14            74                            
  Pathological grade          G1              8      42                               5    26    
  G2                          7               37     11            58                            
  G3                          4               21     3             16                            
  ER/PR status                Negative        4      21                               3    16    
  Positive                    14              74     16            84                            
  Unknown                     1               5      0             0                             
  Her2 status                 Negative        7      36                               19   100   
  Positive                    6               32     0             0                             
  Unknown                     6               32     0             0                             
  Endocrine therapy           Yes             14     74                               14   74    
  No                          5               26     5             26                            
  Chemotherapy                Yes             6      32                               2    11    
  No                          13              68     17            89                            
  BT                          HDR-BT          0      0                                11   58    
  PDR-BT                      0               0      8             42                            

IBTR -- ipsilateral breast tumor recurrence, pN status -- pathological axillary lymph node status, ER/PR status -- hormonal receptor status (negative = estrogen AND progesterone receptor negative), Her2 status -- status of human epidermal growth factor receptor 2, BT -- brachytherapy, HDR-BT and PDR-BT -- high-dose-rate or pulsed-dose-rate multi-catheter interstitial brachytherapy, DCIS -- ductal carcinoma in situ, pT size -- pathological tumor size, EBRT -- external beam radiation therapy

Second breast conserving therapy {#sec3.2}
--------------------------------

Median follow-up for all patients was 66 months after re-treatment of IBTR (range, 18-120 months) and 206 months after initial treatment of the primary tumor (range, 143-375 months). The median time interval between primary tumor and IBTR was 160 months (range, 27-290 months).

The Kaplan-Meier-estimated LC rate was 100% at 5 years, with only one second IBTR after 77 months ([Figure 2](#f0002){ref-type="fig"}), leading to an overall survival rate of 100% at 5 years ([Figure 3](#f0003){ref-type="fig"}). All women were still alive when the analysis was conducted. The only second IBTR occurred 164 months after the first irradiation and 77 months after re-irradiation of the initial IBTR (PDR brachytherapy). In this patient, second IBTR was located in the retroareolar area, which was the same location as the primary tumor. On the contrary, the initial IBTR was diagnosed in the upper lateral quadrant. The diagnosis of second IBTR in this patient was accompanied by the diagnosis of distant metastases including diffuse bone metastases. The patient was treated with mastectomy (R0), and palliative irradiation of bone matastases was performed along with denosumab for osteoprotection. Furthermore, endocrine therapy (fulvestrant) and chemotherapy (paclitaxel) were administered. At the end of follow-up, this patient was still alive (43 months after diagnosis of second IBTR). No further patients were diagnosed with locoregional or distant metastases.

![Kaplan-Meier estimated local control following second BCT, including lumpectomy and partial breast re-irradiation with brachytherapy for IBRT](JCB-11-37355-g002){#f0002}

![Kaplan-Meier estimated overall survival following second BCT, including lumpectomy and partial breast re-irradiation with brachytherapy for IBRT](JCB-11-37355-g003){#f0003}

Toxicity {#sec3.3}
--------

Re-irradiation with brachytherapy was tolerated well with only mild acute toxicity. Only cutaneous erythema and dry desquamation CTCAE grade I-II were diagnosed in 9 patients, respectively. No further acute toxicities occurred. Regarding late toxicity, 63% of patients developed side effects, with fibrosis seen in 37% (7/19) of patients, lipid necrosis in 11% (2/19), hyperpigmentation in 47% (9/19), and telangiectasia in 11% (2/19), respectively. No patient presented with side effects ≥ grade 3. Two patients suffered from fat necrosis in an area of about 3 × 3 cm. These two patients received equal cumulative doses as those without any side effects. One of these women was re-irradiated with HDR brachytherapy, the other with PDR brachytherapy.

Discussion {#sec4}
==========

Salvage mastectomy continues to be the recommended standard therapy in case of IBTR. However, many women facing mastectomy suffer from impaired body image and diminished self-esteem, and express desire for breast preservation if possible \[[@cit0024],[@cit0025],[@cit0026]\]. After second BCT with salvage lumpectomy alone, the rate of local recurrence increased to about 20% \[[@cit0003],[@cit0009],[@cit0011],[@cit0012]\] compared to only 10% in patients treated with salvage mastectomy \[[@cit0003],[@cit0010],[@cit0011],[@cit0012]\]. In the past, there have been concerns about the safety and toxicity of a second course of breast irradiation. However, several studies now suggest that re-irradiation is feasible and safe \[[@cit0003],[@cit0015],[@cit0016],[@cit0017],[@cit0018],[@cit0019],[@cit0027],[@cit0028]\]. The results of the current study are also promising and favorable compared with other analyses \[[@cit0003],[@cit0016],[@cit0018],[@cit0019],[@cit0020]\]. The LC rate was excellent and in the same range as expected for mastectomy with 100% at 5 years. Some minor, mainly retrospective studies also indicate that in selected low-risk patients, similar local recurrence rates to salvage mastectomy can be detected, if adjuvant re-irradiation is added to lumpectomy \[[@cit0003],[@cit0014],[@cit0016],[@cit0017],[@cit0018],[@cit0019],[@cit0020]\]. In a retrospective analysis from 2013, Hannoun-Levi *et al*. reported 5- and 10-year actuarial local control rates of about 94% and 93%, following lumpectomy and re-irradiation using multi-catheter brachytherapy \[[@cit0003]\], and 5-year local control rates of about **77**% in an older study with less selected patients (tumor sizes pT1 to pT3) \[[@cit0016]\]. A study of Deutsch *et al*. from 2002 presented an estimated 5-year disease-free survival rate of only 69% after second BCT and percutaneous re-irradiation. However, in this analysis, insufficient information about appropriate patient selection was reported \[[@cit0014]\]. In another analysis of Kauer-Dorner *et al*., the 5-year local control rate was 93% after re-irradiation. However, only 64% of patients were staged pT1 and only 67% pN0 in this study \[[@cit0020]\]. Notably, the slightly better results of the current study might be explained by careful patient selection, what has been validated by others \[[@cit0029]\]. Second BCT followed by partial breast irradiation was only offered to patients with early-stage low-risk recurrences with favorable tumor characteristics. As a result, the overall survival rate was 100% at 5 years in the present work, supporting BCT plus re-irradiation as an alternative treatment to mastectomy in carefully selected patients.

Additionally, salvage mastectomy is accompanied by a significant impairment of quality of life as well as emotional and physical distress \[[@cit0024],[@cit0025],[@cit0030]\]. After second breast-conserving therapy, patients are known to report significantly better quality of life in respect to body image, social functioning, emotional functioning as well as role functioning when compared to mastectomy \[[@cit0031]\]. Other studies even described significantly increased anxiety and depression levels in women treated with mastectomy compared to BCT (Hospital Anxiety and Depression Scale, 6.96 vs. 7.8 points for anxiety and 6.8 vs. 8.04 points for depression) \[[@cit0032]\]. Younger age was also shown to be an important predictor for greater impairment of quality of life following mastectomy \[[@cit0033]\]. Emotional and social functioning, and financial and future health worries were also significantly worse for younger patients undergoing mastectomy. But even patients with more than 70 years of age, reported higher body image and lifestyle scores when treated with BCT compared to mastectomy \[[@cit0034]\]. However, the diagnosis of breast cancer recurrence itself is already associated with significant changes in quality of life \[[@cit0035]\]. While partnership and family support are the predictors for good quality of life \[[@cit0031]\], family members of breast cancer patients also reported significant impairments in their own emotional well-being \[[@cit0036]\].

The time interval between primary tumor and diagnosis of IBTR is known to be an independent prognostic factor for overall survival, with a better prognosis if the time interval exceeds 36 months \[[@cit0037]\]. In the present study, the median time interval between primary tumor and IBTR was 159.8 months, with no shorter time interval than 36 months in any of the patients. However, some of the breast tumor recurrences in the current study might represent new primary tumors, as in at least 3 cases changes in histology were documented: two patients were diagnosed with invasive lobular carcinomas as primary tumors and invasive ductal carcinomas as IBTR, while one patient suffered from an invasive ductal carcinoma as primary tumor and was diagnosed with an invasive mucinous carcinoma as IBTR. Furthermore, three other women presented with changes in their receptor status: while the primary tumor of two patients was Her2 positive, the local recurrences were Her2 negative. The remaining woman was initially diagnosed with hormone receptor negative breast cancer, while IBTR was an estrogen and progesterone receptor positive tumor. However, this phenomenon is widely known in recurrent disease \[[@cit0038],[@cit0039]\].

The techniques for re-irradiation of the breast are numerous, including conventionally fractionated partial breast external beam re-irradiation \[[@cit0027],[@cit0040]\] or different techniques of intraoperative radiotherapy (IORT) \[[@cit0041],[@cit0042]\]. However, the largest evidence for re-irradiation is found for multi-catheter brachytherapy \[[@cit0043]\]. For accelerated partial breast irradiation, feasibility and effectivity of this technique has already been demonstrated by others \[[@cit0044],[@cit0045]\], and since more than 12 years, multi-catheter brachytherapy has been applied for re-irradiation at the Heidelberg University Hospital. With this technique, side effects were rare in general, with hyperpigmentation and fibrosis representing the most frequent adverse events in the current study. Compared to treatment concepts using partial breast external beam re-irradiation, multi-catheter brachytherapy is associated with superior rates of treatment-related side effects. The NRG Oncology RTOG 1014 trial, a prospective study investigating toxicity, tolerance, and safety of partial external beam re-irradiation for in-breast recurrence, recorded treatment-related skin fibrosis and breast pain adverse events in 71% of cases \[[@cit0027]\]. Meanwhile, the treatment-related toxicity is seen in 63% of patients following multi-catheter brachytherapy in the present study. The slightly higher rate of skin toxicity in the NRG Oncology RTOG1014 trial may be explained by higher skin doses during external beam irradiation. Promising preliminary treatment outcomes of this study have been presented at 2016 Astro Annual Meeting, supporting second breast conservation as an alternative to mastectomy \[[@cit0046]\].

In the present analyzed patient cohort, no pulmonary problems, rib fractures, or second malignancies have been reported so far. However, the percentage of late side effects may increase with a longer follow-up. While in the present cohort, late side effects in general were similar or lower than in the literature \[[@cit0020],[@cit0047]\]; 47% of patients had hyperpigmentation compared to reported rates of 9% to 29% in the literature \[[@cit0019],[@cit0020],[@cit0047]\]. This may be explained by the retrospective character of the present work. Hyperpigmentation due to the primary irradiation was not taken into account, as baseline hyperpigmentation has not been documented. Reported rates of fat necrosis after interstitial brachytherapy of about 20%, as observed by Budrukkar *et al*. \[[@cit0048]\], could not be confirmed in our study as fat necrosis was noticed only in 10% of patients.

Limitations in the current work are mainly due to the retrospective character of the analysis. Furthermore, due to careful patient selection and a low a priori risk of IBTR after first BCT, the present single center cohort of 10-year experience in partial breast re-irradiation is rather small. Although, 10-year experiences are already scarce in the application of modern techniques, an even longer follow-up of 10 to 20 years would be needed for sufficient evidence. A precise differentiation between true local recurrences and new primaries arising in the treated breast was not possible. Long interval between first BCT and IBTR as well as differences in histology suggest that some patients included in this analysis might have had new primaries. This may have positively influenced the oncological outcome observed in this analysis \[[@cit0049]\]. Nevertheless, this study provides encouraging data for the feasibility, safety, and efficacy of a second BCT with lumpectomy followed by partial breast re-irradiation in case of IBTR. For highly selected patients with low-risk recurrences, this treatment approach allows avoiding salvage mastectomy, which is often accompanied by severe impairments in quality of life and body image. Our data confirm that a repeated course of irradiation following second lumpectomy due to IBTR appears to be a reasonable alternative to mastectomy, at least for some patients. This is supported by current national and international guidelines recommending that individualized treatment strategies including second BCT should be considered and discussed by multidisciplinary tumor boards \[[@cit0003],[@cit0043],[@cit0050]\]. Randomized controlled trials comparing salvage mastectomy to second BCT including re-irradiation are urgently needed for an well-founded assessment whether mastectomy can be avoided for selected patients in the future \[[@cit0050]\]. However, conducting such a trial may be futile due to patients' preferences regarding randomization between second BCT and mastectomy.

Conclusions {#sec5}
===========

The current study demonstrates that in patients with small, low-risk local breast tumor recurrences, local control rates after second BCT with salvage lumpectomy and partial breast re-irradiation are comparable to those after mastectomy. This analysis provides encouraging data for the feasibility, safety, and efficacy of a second BCT. Our results may support a rational discussion about the opportunity of second BCT followed by partial breast irradiation for selected low-risk patients.
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